ArticleCureus2025
Primary Cutaneous Carcinosarcoma: A Literature Review and a Report of Two Cases.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinosarcomas are rare malignant tumors with both epithelial and mesenchymal components, classified into visceral and cutaneous subtypes. Primary cutaneous carcinosarcoma (PCS) is exceptionally rare, and robust evidence to guide its management is lacking. This study aims to consolidate current knowledge on PCS through two new case reports and a comprehensive literature review, offering insights into its pathogenesis, clinical features, and management strategies. Two cases of PCS managed by a multidisciplinary team were reported, detailing clinical, histopathological, and immunohistochemical findings. A systematic literature review of PCS cases published between 2001 and 2021 was conducted, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and collating data on clinical presentation, histology, treatment, and outcomes. Literature analysis identified 74 patients across 42 case reports. Histopathology reveals a frequent epithelial component of squamous cell carcinoma (43.2%) or basal cell carcinoma (27.0%). Immunohistochemistry (IHC) aids diagnosis, with vimentin marking mesenchymal components. Surgical excision is the primary treatment; recurrence occurs in 16.2% of cases. Prognosis varies, with better outcomes linked to epithelial subtypes. PCS remains a diagnostic and therapeutic challenge due to its rarity and lack of standardized guidelines. This study highlights the importance of histopathology, IHC, and multidisciplinary management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.